124 related articles for article (PubMed ID: 38663028)
1. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.
Lee CK; Atibalentja DF; Yao LE; Park J; Kuruvilla S; Felsher DW
Nanotheranostics; 2022; 6(3):243-255. PubMed ID: 35145835
[No Abstract] [Full Text] [Related]
3. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
5. Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer.
Ding D; Liang R; Li T; Lan T; Li Y; Huang S; He G; Ren J; Li W; Zheng Z; Chen T; Fang J; Huang L; Shuai X; Wei B
J Control Release; 2024 May; 369():309-324. PubMed ID: 38554771
[TBL] [Abstract][Full Text] [Related]
6. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
[TBL] [Abstract][Full Text] [Related]
7. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
[TBL] [Abstract][Full Text] [Related]
8. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
9. Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis.
Liu H; Deng R; Zhu CW; Han HK; Zong GF; Ren L; Cheng P; Wei ZH; Zhao Y; Yu SY; Lu Y
Acta Pharmacol Sin; 2024 Jan; 45(1):193-208. PubMed ID: 37749237
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with 17β-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model.
Song CH; Kim N; Nam RH; Choi SI; Jang JY; Kim JW; Na HY; Lee HN
Cancer Lett; 2022 Sep; 543():215780. PubMed ID: 35690286
[TBL] [Abstract][Full Text] [Related]
12. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
13. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
Shi Y; Fu Y; Zhang X; Zhao G; Yao Y; Guo Y; Ma G; Bai S; Li H
Cancer Immunol Immunother; 2021 Jan; 70(1):61-73. PubMed ID: 32632663
[TBL] [Abstract][Full Text] [Related]
14. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
17. Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice.
Li N; Tang J; Yang J; Zhu B; Wang X; Luo Y; Yang H; Jang F; Zou J; Liu Z; Wang Z
Cancer Lett; 2021 Feb; 498():121-129. PubMed ID: 33129956
[TBL] [Abstract][Full Text] [Related]
18. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
[TBL] [Abstract][Full Text] [Related]
19. Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity.
Yang S; Shim MK; Song S; Cho H; Choi J; Jeon SI; Kim WJ; Um W; Park JH; Yoon HY; Kim K
Biomaterials; 2022 Nov; 290():121841. PubMed ID: 36206664
[TBL] [Abstract][Full Text] [Related]
20. Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model.
Goshima T; Ieguchi K; Onishi N; Shimizu T; Takayanagi D; Watanabe M; Fujimoto Y; Ohkuma R; Suzuki R; Tsurui T; Mura E; Iriguchi N; Ishiguro T; Shimokawa M; Hirasawa Y; Kubota Y; Ariizumi H; Horiike A; Yoshimura K; Tsuji M; Kiuchi Y; Kobayashi S; Fujishiro J; Hoffman RM; Tsunoda T; Wada S
Anticancer Res; 2024 Jan; 44(1):23-29. PubMed ID: 38159965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
